Subtopic Deep Dive

← Eicosanoids and Hypertension Pharmacology

Cytochrome P450 Epoxygenases in Hypertension
Research Guide

What is Cytochrome P450 Epoxygenases in Hypertension?

Cytochrome P450 epoxygenases are enzymes that metabolize arachidonic acid to epoxyeicosatrienoic acids (EETs), which regulate vascular tone and blood pressure in hypertension.

CYP2J2 and CYP2C8/9 epoxygenases produce EETs that promote vasodilation and inhibit inflammation in vascular endothelium (Fleming, 2001; 382 citations). These enzymes modulate TRPV4 channels to control endothelial calcium influx and vascular function (Vriens et al., 2005; 356 citations). Over 20 papers characterize their role in hypertension models via genetic polymorphisms and induction studies.

Curated Papers

Key Challenges

Why It Matters

CYP epoxygenases explain hypertension variability through EET-mediated vascular protection, guiding personalized therapies targeting CYP2J2 polymorphisms (Fleming, 2001). EETs from these enzymes reduce blood pressure in animal models by enhancing endothelial function and countering 20-HETE vasoconstriction (Wang et al., 2021; Miyata and Roman, 2005). Clinical profiling of oxylipins via LC-MS/MS reveals CYP-derived EET dysregulation in hypertensive patients, enabling biomarker-driven pharmacotherapy (Strassburg et al., 2012).

Key Research Challenges

Tissue-specific CYP expression

Variable CYP2J2 and CYP2C8/9 expression across vascular beds complicates hypertension modeling (Fleming, 2001). Endothelial-specific induction alters EET levels differently in arteries versus kidneys (Vriens et al., 2005).

EET stability and degradation

Soluble epoxide hydrolase rapidly degrades EETs, reducing their antihypertensive effects (Panigrahy et al., 2011; 287 citations). Balancing epoxygenase induction with hydrolase inhibition remains unoptimized in models.

Genetic polymorphism impacts

CYP2J2 variants alter enzyme kinetics and hypertension risk, but human translation from rodent models lags (Wang et al., 2021). Quantifying polymorphism-EET interactions requires advanced omics (Buczynski et al., 2009).

Essential Papers

Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: A current perspective

Samik Bindu, Somnath Mazumder, Uday Bandyopadhyay · 2020 · Biochemical Pharmacology · 1.7K citations

Metabolism pathways of arachidonic acids: mechanisms and potential therapeutic targets

Bei Wang, Lujin Wu, Jing Chen et al. · 2021 · Signal Transduction and Targeted Therapy · 1.2K citations

Vascular Endothelial Cell Biology: An Update

Anne Krüger‐Genge, Anna Blocki, Ralf‐Peter Franke et al. · 2019 · International Journal of Molecular Sciences · 1.1K citations

The vascular endothelium, a monolayer of endothelial cells (EC), constitutes the inner cellular lining of arteries, veins and capillaries and therefore is in direct contact with the components and ...

Thematic Review Series: Proteomics. An integrated omics analysis of eicosanoid biology

Matthew W. Buczynski, Darren S. Dumlao, Edward A. Dennis · 2009 · Journal of Lipid Research · 517 citations

Arachidonic Acid Metabolites in Cardiovascular and Metabolic Diseases

Thomas Sonnweber, Alex Pizzini, Manfred Nairz et al. · 2018 · International Journal of Molecular Sciences · 420 citations

Lipid and immune pathways are crucial in the pathophysiology of metabolic and cardiovascular disease. Arachidonic acid (AA) and its derivatives link nutrient metabolism to immunity and inflammation...

Cytochrome P450 and Vascular Homeostasis

Ingrid Fleming · 2001 · Circulation Research · 382 citations

Since the initial reports that renal cytochrome P450 (CYP) enzymes can metabolize arachidonic acid to substances which affect arterial tone, it has become increasingly clear that CYP enzymes expres...

Modulation of the Ca <sup>2</sup> Permeable Cation Channel TRPV4 by Cytochrome P450 Epoxygenases in Vascular Endothelium

Joris Vriens, Grzegorz Owsianik, Beate Fißlthaler et al. · 2005 · Circulation Research · 356 citations

TRPV4 is a broadly expressed Ca 2+ -permeable cation channel in the vanilloid subfamily of transient receptor potential channels. TRPV4 gates in response to a large variety of stimuli, including ce...

Reading Guide

Foundational Papers

Start with Fleming (2001; 382 citations) for core CYP-vascular role, then Vriens et al. (2005; 356 citations) for endothelial TRPV4 mechanisms, and Buczynski et al. (2009; 517 citations) for eicosanoid omics context.

Recent Advances

Wang et al. (2021; 1243 citations) details AA metabolism targets; Sonnweber et al. (2018; 420 citations) links AA metabolites to cardiovascular disease.

Core Methods

Arachidonic acid incubation with CYP enzymes produces EETs; LC-MS/MS quantifies oxylipins (Strassburg et al., 2012); electrophysiology measures TRPV4 currents (Vriens et al., 2005).

How PapersFlow Helps You Research Cytochrome P450 Epoxygenases in Hypertension

Discover & Search

Research Agent uses citationGraph on Fleming (2001; 382 citations) to map 50+ connected papers on CYP epoxygenases in vascular homeostasis, then exaSearch for 'CYP2J2 polymorphisms hypertension' to uncover tissue-specific studies like Vriens et al. (2005).

Analyze & Verify

Analysis Agent applies readPaperContent to extract EET kinetics from Wang et al. (2021), then runPythonAnalysis with pandas to quantify oxylipin profiles from Strassburg et al. (2012) LC-MS/MS data; verifyResponse via CoVe cross-checks claims against Buczynski et al. (2009) omics, with GRADE scoring evidence strength for TRPV4 modulation.

Synthesize & Write

Synthesis Agent detects gaps in EET-hydrolase balance across Fleming (2001) and Panigrahy (2011), flagging contradictions in vascular models; Writing Agent uses latexSyncCitations to integrate 20 references, latexCompile for figure-ready manuscripts, and exportMermaid for CYP arachidonic acid pathway diagrams.

Use Cases

"Analyze EET concentration correlations with blood pressure in CYP knockout models"

Research Agent → searchPapers 'CYP epoxygenase hypertension models' → Analysis Agent → runPythonAnalysis (pandas/matplotlib on extracted oxylipin data from Strassburg et al., 2012) → correlation heatmap and p-values.

"Draft LaTeX review on CYP2J2 variants in human hypertension"

Synthesis Agent → gap detection on Fleming (2001) cluster → Writing Agent → latexEditText for sections + latexSyncCitations (20 papers) + latexCompile → camera-ready PDF with EET pathway figure.

"Find GitHub code for CYP epoxygenase kinetic modeling"

Research Agent → paperExtractUrls from Vriens et al. (2005) → Code Discovery → paperFindGithubRepo → githubRepoInspect → runnable Python scripts for TRPV4-EET simulations.

Automated Workflows

Deep Research workflow scans 50+ papers via citationGraph from Fleming (2001), generating structured reports on CYP-EET-hypertension links with GRADE grading. DeepScan applies 7-step CoVe to verify polymorphism claims in Wang et al. (2021), checkpointing against Buczynski et al. (2009) omics. Theorizer builds hypotheses on CYP induction therapies from Vriens et al. (2005) TRPV4 data.

Try Doxa for Cytochrome P450 Epoxygenases in Hypertension Research

Frequently Asked Questions

What defines cytochrome P450 epoxygenases in hypertension?

CYP2J2 and CYP2C8/9 enzymes convert arachidonic acid to EETs, which vasodilate vessels and lower blood pressure (Fleming, 2001).

What methods study CYP epoxygenases?

LC-MS/MS profiles oxylipins (Strassburg et al., 2012); genetic models test polymorphisms (Wang et al., 2021); patch-clamp assays TRPV4 modulation (Vriens et al., 2005).

What are key papers?

Fleming (2001; 382 citations) on vascular homeostasis; Vriens et al. (2005; 356 citations) on TRPV4; Wang et al. (2021; 1243 citations) on metabolism pathways.